Live Breaking News & Updates on Co Development Collaboration

Press release content from Business Wire. The AP news staff was not involved in its creation.
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
March 15, 2021 GMT
MALVERN, Pa. & SAN DIEGO (BUSINESS WIRE) Mar 15, 2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.
ADVERTISEMENT
“Throughout 2020, PhaseBio made significant progress advancing our pipeline of therapies for serious cardiopulmonary diseases,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. “Our progress was driven by the continued global expansion of the pivotal Phase 3 REVERSE-IT trial of our lead product candidate bentracimab, whi ....

San Diego , United States , John Sharp , Alexc Sapir , Phasebio Pharmaceuticals Inc , Pulmonary Vascular Research Institute , Selenity Pharmaceuticals Bermuda Ltd , Canale Communications Inc , European Union , Committee For Medicinal Products Human Use , Development Collaboration , Viamet Pharmaceuticals Holdings , Drug Administration , World Congress On , Bentracimab Clinical Development Plan , Exchange Commission , Phasebio Pharmaceuticals , European Medicines Agency , Bentracimab To Support Development , Chief Executive Officer , Biologics License Application , Supply Agreement , Support Development , Dosed First Patients , Intervention Trial , Written Scientific Advice ,